Advertisement
Singapore markets closed
  • Straits Times Index

    3,300.04
    -3.15 (-0.10%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • Dow

    38,852.27
    +176.59 (+0.46%)
     
  • Nasdaq

    16,349.25
    +192.92 (+1.19%)
     
  • Bitcoin USD

    64,094.82
    -87.23 (-0.14%)
     
  • CMC Crypto 200

    1,327.00
    -38.12 (-2.79%)
     
  • FTSE 100

    8,299.02
    +85.53 (+1.04%)
     
  • Gold

    2,322.90
    -8.30 (-0.36%)
     
  • Crude Oil

    78.18
    -0.30 (-0.38%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • Nikkei

    38,835.10
    +599.03 (+1.57%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • FTSE Bursa Malaysia

    1,605.68
    +8.29 (+0.52%)
     
  • Jakarta Composite Index

    7,123.61
    -12.28 (-0.17%)
     
  • PSE Index

    6,618.58
    -33.91 (-0.51%)
     

AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.